Cytokine Market Growth, Demand and Challenges of the Key Industry Players 2024-32
                     Global Cytokine 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  to  the  la tes t  repor t  by  IMARC Group ,  t i t l ed  "Cytok ine  Market :  
Globa l  Industry  Trends,  Share ,  S ize ,  Growth,  Opportuni ty  and Forecas t  
2024 -2032 ,"  the  g loba l  cy tok ine  marke t  s i ze  reached  US$ 89 .6  B i l l i on  in  2023 .
Factors Af fect ing the Growth of  the Cytokine Industry:
Report Increasing Prevalence of  Chronic Diseases:
The g loba l  p reva lence  o f  ch ron ic  d iseases  i s  pos i t i ve ly  impac t ing  the  marke t .  
Highlight and Chron ic  d iseases  such  as  cancer ,  au to immune d iseases ,  and  va r ious  
in f lammatory  d iso rders  a re  becoming  inc reas ing ly  common and  pose  
s ign i f i can t  hea l th  cha l lenges .  Cy tok ines ,  s igna l ing  p ro te ins  p roduced  by  
Description immune ce l l s ,  p lay  a  key  ro le  in  regu la t ing  immune responses .  
Th is  v i ta l i t y  has  led  to  an  inc rease  in  resea rch  and  deve lopment  (R&D)  e f fo r ts  
a imed  a t  leve rag ing  cy tok ines  to  deve lop  innova t i ve  the rapeu t i cs .  Cy tok ine -
based  the rap ies  have  shown p romise  in  modu la t ing  immune  responses  in  
pa t ien ts  su f fe r ing  f rom d iseases  such  as  rheumato id  a r th r i t i s ,  Crohn 's  d isease ,  
and  pso r ias is .
Advancements in Biotechnology and Research:
Cont inuous advances  in  b io techno logy and  research a re  d r iv ing  market  
growth.  These  advances are  improv ing  the  unders tand ing  o f  cy tok ine  
b io logy ,  i t s  func t ions ,  and  i t s  potent ia l  app l i ca t ions in  the  medica l  f ie ld .  As 
sc ien t i s ts  unrave l  the  in t r icac ies  o f  cy tok ine  s igna l ing pathways and  the i r  
Report ro le  in  immune regu la t ion ,  new avenues  o f  therapeut ic  in terven t ion  are  
opening  up.  
Highlight and An area  o f  notab le  advancement  is  the deve lopment  o f  immunotherapy.  
Cytok ines such  as  in ter leuk in -2  ( IL -2)  and in te r fe rons have been u t i l i zed in  
Description cancer  immunotherapy to  enhance the immune response  aga ins t  cancer  
ce l l s .
Improvements in Pharmaceutical  Industry:
The ever - increas ing  focus on  persona l ized med ic ine  i s  dr i v ing demand for  
cy tok ines  in  the pharmaceut ica l  indust ry .  Pharmaceut ica l  compan ies  have 
recogn ized  the poten t ia l  o f  cy tok ine-based therapeut ics  to  address 
prev ious ly  un t rea tab le  cond i t ions  and  a re  ac t ive ly  pursu ing research  and 
deve lopment  (R&D)  in  th is  d i rec t ion.
Col labora t ions  be tween  pharmaceu t ica l  compan ies  and  academic  research  
ins t i tu tes  a re  becoming  inc reas ing ly  p reva len t ,  f os te r ing  an  env i ronment  
conduc ive  to  innova t ion  in  cy tok ine -based  d rug  deve lopment .  These  
par tne rsh ips  fac i l i ta te  knowledge  and  resource  shar ing ,  a l low ing  fo r  the  rap id  
Report t rans la t ion  o f  bas ic  research  f ind ings  in to  c l in i ca l  app l ica t ions .
Highlight and Request  for  a  PDF sample  o f  th is  repor t :  
h t tps : / /www. imarcgroup .com/cy tok ine -marke t / reques tsamp le
Description
Report Description
Global  Cytokine Market Trends:
Elder ly  people are more suscept ib le to a var ie ty  o f  chron ic  d iseases and cond i t ions,  inc lud ing cancer  
and auto immune d iseases.  As the number  o f  e lder ly  peop le wor ldwide increases,  so  does the number  of  
pat ients  requi r ing cytok ine-based therapies .  Cytok ine therap ies  are  par t icu lar ly  va luable  in  address ing 
age-re lated d iseases and age-re lated dec l ines  in  immune func t ion,  making them a key component  o f  
hea l thcare for  o lder  adu l ts .  Approva l  o f  cy tok ine-based therap ies  by regula tory  author i t ies  is  suppor t ing 
market  growth.  
As more cytok ine-based drugs receive regula tory  approval ,  they become avai lab le to  a  wider  pat ient  
popula t ion,  fur ther  fuel ing market  expansion.  Fur thermore,  the in i t ia t ion of  c l in ica l  t r ia ls  of  new cytok ine 
therap ies  demonst rates the potent ia l  o f  these t reatments ,  at t rac t ing investment  and fur ther  research.
View Report  TOC, Figures and Tables :  ht tps: / /www.imarcgroup.com/cytokine-market
Breakup by Cytokine Type:
• Tumor Necrosis  Factor-TNF
• Inter leukins- I l
• Interferons- IFN
• Epidermal  Growth Factor-EGF
• Others
Report 
Breakup by Therapeutic Application:
Segmentation • Cancer
• Asthma and Airway Infl ammation
• Arthri t is
• Others
Breakup by End User:
• Pharmaceutical  and Biotechnology Companies
• Contract Research Organizations
• Academic and Research Insti tutes
Breakup by Region:
• North America
• Asia-Pacifi c
Report 
• Europe
Segmentation • Latin America
• Middle East and Afr ica
• AbbVie Inc.
• Abcam plc
• Amgen Inc.
Competitive • Appl ied Biological Materials Inc. (abm)
• Bio-Techne Corporation
Landscape 
• F. Hoff mann-La Roche AG
with Key • GenScript Biotech Corporation
Players • Randox Laboratories Ltd.
• Thermo Fisher Scient ifi c Inc.
• UCB S.A.
How has the global cytokine market performed so 
far and how will it perform in the coming years?
What has been the impact of COVID-19 on the 
global cytokine market?
Key 
What are the key regional markets?
Questions 
Answered in 
What is the breakup of the market based on the 
the Report cytokine type?
What is the breakup of the market based on the 
therapeutic application?
What is the breakup of the market based on the 
end user?
What are the various stages in the value chain of 
the industry?
What are the key driving factors and challenges in 
the industry?
Key 
Questions What is the structure of the global cytokine market 
and who are the key players?
Answered in 
the Report What is the degree of competition in the industry?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  C y t o k i n e  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  C y t o k i n e  T y p e
    6 . 1     T u m o r  N e c r o s i s  F a c t o r - T N F
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     I n t e r l e u k i n s - I l
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     I n t e r f e r o n s - I F N
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
       
    6 . 4     E p i d e r m a l  G r o w t h  F a c t o r - E G F
        6 . 4 . 1  M a r k e t  T r e n d s
        6 . 4 . 2  M a r k e t  F o r e c a s t
    6 . 5     O t h e r s
        6 . 5 . 1  M a r k e t  T r e n d s
        6 . 5 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  T h e r a p e u t i c  A p p l i c a t i o n
    7 . 1     C a n c e r
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     A s t h m a  a n d  A i r w a y  I n f l a m m a t i o n
Table of         7 . 2 . 1  M a r k e t  T r e n d s        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     A r t h r i t i s
        7 . 3 . 1  M a r k e t  T r e n d s
Contents         7 . 3 . 2  M a r k e t  F o r e c a s t    7 . 4     O t h e r s
        7 . 4 . 1  M a r k e t  T r e n d s
        7 . 4 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  E n d  U s e r
    8 . 1     P h a r m a c e u t i c a l  a n d  B i o t e c h n o l o g y  C o m p a n i e s
        8 . 1 . 1  M a r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t
    8 . 2     C o n t r a c t  R e s e a r c h  O r g a n i z a t i o n s
        8 . 2 . 1  M a r k e t  T r e n d s
        8 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 3     A c a d e m i c  a n d  R e s e a r c h  I n s t i t u t e s
        8 . 3 . 1  M a r k e t  T r e n d s
        8 . 3 . 2  M a r k e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /c y to k i ne -m a rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: